机构:[1]Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515[2]Department of Gynecology, Fourth Hospital, Hebei Medical University, Shijiazhuang, Hebei 050000临床科室妇科河北医科大学第四医院[3]Department of Gynecology, Qingdao Municipal Hospital, Qingdao, Shandong 266000[4]Department of Obstetrics and Gynecology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi 030000[5]Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000[6]Department of Obstetrics and Gynecology, China‑Japan Friendship Hospital, Beijing 100000[7]Department of Gynecology, The Affiliated Hospital of Qingdao University Medical College, Qingdao, Shandong 266000, P.R. China
Brain-derived neurotrophic factor (BDNF), tropomyosin receptor kinase B (TrkB), vascular endothelial growth factor (VEGF) and CD105 are highly expressed in several types of cancer. The present study aimed to determine whether BDNF, TrkB, VEGF and CD105 are associated with the prognosis and metastasis of patients with cervical squamous cell carcinoma (SCC) at the IB2 stage. A total of 79 patients with IB2-stage SCC were enrolled in the present study. The expression levels of BDNF, TrkB, VEGF and CD105 in IB2-stage cervical cancer tissue were detected by immunohistochemistry and their association with clinicopathological indexes or prognostic factors was statistically analyzed. Reverse transcription quantitative PCR was used to detect whether the expression of VEGF was affected in SiHa cells co-cultured with BDNF. In addition, BDNF-induced SiHa cell migration and invasion were examined. BDNF expression in the cervical cancer samples was significantly associated with positive lymphovascular space invasion (P<0.001) and pelvic lymph node metastasis (P<0.05). In addition, microvessel density was verified as an independent prognostic factor for overall survival (P<0.05). In vitro analysis indicated that BDNF significantly induced cellular migration and invasion of SiHa cells in a dose-dependent manner (P<0.001). BDNF induced the expression of VEGF in SiHa cells, which was inhibited by BDNF antibodies or an inhibitor of TrkB receptor (P<0.05). BDNF may be considered a useful indicator of pelvic metastasis, which is involved in the aggressive spread of IB2-stage SCC. BDNF-induced upregulation of VEGF was revealed to act as a pro-angiogenic factor in SCC (Trial registration no. http://apps.who.int/trialsearch/; ChiCTR1800017778).
基金:
This study was supported by key projects of the National
Science & Technology Pillar Program during the Twelfth
Five‑year Plan Period (grant no. 2014BAI05B03), the
National Natural Science Foundation of Guangdong,
China (grant no. 2015A030311024), the Medical Research
Foundation of Guangdong, China (grant no. A2015063) and
the Presidential Foundation of Nanfang Hospital of Southern
Medical University (grant no. 2015C015).
第一作者机构:[1]Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515
共同第一作者:
通讯作者:
通讯机构:[1]Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515[*1]Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, 1,838 Guangzhou North Avenue, Guangzhou, Guangdong 510515, P.R. China
推荐引用方式(GB/T 7714):
YINGYING QI,WEILI LI,SHAN KANG,et al.Expression of BDNF, TrkB, VEGF and CD105 is associated with pelvic lymph node metastasis and prognosis in IB2-stage squamous cell carcinoma[J].EXPERIMENTAL AND THERAPEUTIC MEDICINE.2019,18(6):4221-4230.doi:10.3892/etm.2019.8100.
APA:
YINGYING QI,WEILI LI,SHAN KANG,LONG CHEN,MIN HAO...&PING LIU.(2019).Expression of BDNF, TrkB, VEGF and CD105 is associated with pelvic lymph node metastasis and prognosis in IB2-stage squamous cell carcinoma.EXPERIMENTAL AND THERAPEUTIC MEDICINE,18,(6)
MLA:
YINGYING QI,et al."Expression of BDNF, TrkB, VEGF and CD105 is associated with pelvic lymph node metastasis and prognosis in IB2-stage squamous cell carcinoma".EXPERIMENTAL AND THERAPEUTIC MEDICINE 18..6(2019):4221-4230